texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials
print
Texas Oncology-Austin Central
6204 Balcones Drive, Austin, TX 78731
T: 512-427-9400
After HoursT: 512-427-9400
Hours of Operation:




Pharmacy Hours of Operation:




New Patient Forms

Texas Oncology-Austin Central Research and Clinical Trials

We participate in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials. Learn more and see a list of current trials.

Biliary Cancer

Phase: II

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Bladder Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Brain Cancer

Phase: II

Title: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma View

Breast Cancer

Phase: II

Title: (USO 11025/ Novartis CBKM120ZUS39T) Phase II Multicenter Single-arm Study of BKM120 plus Capecitabine for Breast Cancer Patients with Brain Metastases View

Phase: II

Title: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View

Phase: III

Title: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304) View

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: III

Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003) View

Phase: II

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Phase: II

Title: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy (G1T28-04) View

Phase: II

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Phase: III

Title: A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522 View

Phase:

Title: MRI evaluation of breast tumor growth and treatment response View

Cervical Cancer

Phase: III

Title: A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL(ANZGOG 0902/GOG-0274/RTOG 1174) View

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Colon Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: III

Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177) View

Phase: III

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Endometrial Cancer

Phase: II/III

Title: GOG-0286b: a randomized phase II/III study of paclitaxel/carboplatin/metformin (nsc#91485) versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVa, stage IVb, or recurrent endometrial cancer NCT #02065687 View

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Esophageal Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: III

Title: A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians'' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181) View

Fallopian Tube Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Gall Bladder Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Gastric Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: III

Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GS-US-296-1080) View

GI Stromal Tumor (GIST)

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Head and Neck Cancer

Phase: III

Title: A phase III study of postoperative radiation therapy (IMRT) +/- cetuximab for locally-advanced resected head and neck cancer (RTOG 0920) View

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Leukemia

Phase: II

Title: A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies (GS-US-339-0102) View

Phase: IV

Title: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) View

Phase: II

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Phase: III

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Phase: II

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Liver Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Lung Cancer

Phase: II

Title: CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: III

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Phase: II

Title: A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen (MS200095-0022) View

Phase: III/IV

Title: CA209-817: A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer View

Phase: III

Title: Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816) View

Lymphomas

Phase: II

Title: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View

Phase: II

Title: A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies (GS-US-339-0102) View

Phase: III

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: II

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma (UTX-TGR-205) View

Melanoma

Phase:

Title: A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma (S1404) View

Phase:

Title: A US MULTI-SITE OBSERVATIONAL STUDY IN PATIENTS WITH UNRESECTABLE AND METASTATIC MELANOMA: THE OPTIMIZE STUDY View

Mesothelioma

Phase: II/III

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Myelomas

Phase: III

Title: A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185) View

Phase: III

Title: A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM). (KEYNOTE 183) View

Phase: IV

Title: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) View

Phase: II

Title: Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects with Multiple Myeloma (54767414MMY2012) View

Neuroendocrine Tumors

Phase: III

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Ovarian Cancer

Phase: III

Title: (ET743-OVC-3006) A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer View

Phase: II

Title: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens - Tesaro PR-30-5020-C - QUADRA View

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: III

Title: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer View

Phase: III

Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER (B9991010) View

Phase: II/III

Title: FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (OX4325) View

Phase: III

Title: PR-30-5017-C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy (PRIMA) View

Pancreatic Cancer

Phase: III

Title: A Phase II-R and A Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (RTOG 0848) View

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: II

Title: MM-141-07-02-02: A randomized, double-blind, placebo-controlled phase 2 study of MM-141 plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE) View

Prostate Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: III

Title: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESISINHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN - Roche CO39385 View

Rectal Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: III

Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177) View

Renal Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase: III

Title: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma (AV-951-15-303) View

Phase: III/IV

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Solid Tumors

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Testicular Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Thyroid Cancer

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Urothelial Cancer

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

No Phase

Indication: Melanoma

Title: A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma (S1404) View

Indication: Melanoma

Title: A US MULTI-SITE OBSERVATIONAL STUDY IN PATIENTS WITH UNRESECTABLE AND METASTATIC MELANOMA: THE OPTIMIZE STUDY View

Indication: Breast Cancer

Title: MRI evaluation of breast tumor growth and treatment response View

Phase II

Indication: Biliary Cancer

Title: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202) View

Indication: Bladder Cancer

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Bladder Cancer

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Brain Cancer

Title: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma View

Indication: Breast Cancer

Title: (USO 11025/ Novartis CBKM120ZUS39T) Phase II Multicenter Single-arm Study of BKM120 plus Capecitabine for Breast Cancer Patients with Brain Metastases View

Indication: Breast Cancer

Title: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer View

Indication: Breast Cancer

Title: A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer.(INO-VT-464-CL-006) View

Indication: Breast Cancer

Title: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy (G1T28-04) View

Indication: Breast Cancer

Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) (ONT-380-206) View

Indication: Leukemia

Title: A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies (GS-US-339-0102) View

Indication: Leukemia

Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208) View

Indication: Leukemia

Title: (UTX-TGR-204) A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 View

Indication: Lung Cancer

Title: CA209370: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies View

Indication: Lung Cancer

Title: A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen (MS200095-0022) View

Indication: Lymphomas

Title: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above View

Indication: Lymphomas

Title: A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies (GS-US-339-0102) View

Indication: Lymphomas

Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma (UTX-TGR-205) View

Indication: Myelomas

Title: Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects with Multiple Myeloma (54767414MMY2012) View

Indication: Ovarian Cancer

Title: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens - Tesaro PR-30-5020-C - QUADRA View

Indication: Pancreatic Cancer

Title: MM-141-07-02-02: A randomized, double-blind, placebo-controlled phase 2 study of MM-141 plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE) View

Indication: Urothelial Cancer

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Indication: Urothelial Cancer

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201) View

Phase II/III

Indication: Endometrial Cancer

Title: GOG-0286b: a randomized phase II/III study of paclitaxel/carboplatin/metformin (nsc#91485) versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVa, stage IVb, or recurrent endometrial cancer NCT #02065687 View

Indication: Mesothelioma

Title: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed/cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma (1199.93) View

Indication: Ovarian Cancer

Title: FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (OX4325) View

Phase III

Indication: Bladder Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Breast Cancer

Title: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304) View

Indication: Breast Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Breast Cancer

Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003) View

Indication: Breast Cancer

Title: A Phase III Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) MK-3475-522 View

Indication: Cervical Cancer

Title: A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL(ANZGOG 0902/GOG-0274/RTOG 1174) View

Indication: Cervical Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Colon Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Colon Cancer

Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177) View

Indication: Colon Cancer

Title: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3) View

Indication: Endometrial Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Esophageal Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Esophageal Cancer

Title: A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians'' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181) View

Indication: Fallopian Tube Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Gall Bladder Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Gastric Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Gastric Cancer

Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GS-US-296-1080) View

Indication: GI Stromal Tumor (GIST)

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Head and Neck Cancer

Title: A phase III study of postoperative radiation therapy (IMRT) +/- cetuximab for locally-advanced resected head and neck cancer (RTOG 0920) View

Indication: Head and Neck Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Leukemia

Title: (UTX-TGR-304) Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) View

Indication: Liver Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Lung Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Lung Cancer

Title: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer - Ariad AP26113-13-301 View

Indication: Lung Cancer

Title: Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816) View

Indication: Lymphomas

Title: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008) View

Indication: Lymphomas

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Myelomas

Title: A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185) View

Indication: Myelomas

Title: A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM). (KEYNOTE 183) View

Indication: Neuroendocrine Tumors

Title: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328 View

Indication: Ovarian Cancer

Title: (ET743-OVC-3006) A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer View

Indication: Ovarian Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Ovarian Cancer

Title: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer View

Indication: Ovarian Cancer

Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER (B9991010) View

Indication: Ovarian Cancer

Title: PR-30-5017-C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy (PRIMA) View

Indication: Pancreatic Cancer

Title: A Phase II-R and A Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (RTOG 0848) View

Indication: Pancreatic Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Prostate Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Prostate Cancer

Title: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESISINHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN - Roche CO39385 View

Indication: Rectal Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Rectal Cancer

Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177) View

Indication: Renal Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Title: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma (AV-951-15-303) View

Indication: Solid Tumors

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase III/IV

Indication: Lung Cancer

Title: CA209-817: A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer View

Indication: Renal Cancer

Title: Phase 3b/4 Safety Trial Of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC (CA209-920) View

Phase IV

Indication: Leukemia

Title: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA) View

Indication: Myelomas

Title: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001) View